|United States Patent||7,943,173|
|Breder , et al.||May 17, 2011|
Disclosed in certain embodiments is a pharmaceutical composition comprising from 10 to 40 mg of oxycodone or a pharmaceutically acceptable salt thereof and 0.65 to 0.90 mg naloxone or a pharmaceutically acceptable salt thereof.
|Inventors:||Breder; Christopher D. (Greenwich, CT), Colucci; Robert D. (Newtown, CT), Howard; Stephen A (Danbury, CT), Oshlack; Benjamin (New York, NY), Wright; Curtis (Norwalk, CT)|
Purdue Pharma L.P.
|Filed:||July 18, 2002|
|Application Number||Filing Date||Patent Number||Issue Date|
|Current U.S. Class:||424/484 ; 424/457; 424/468|
|Current International Class:||A61K 9/14 (20060101); A61K 9/22 (20060101); A61K 9/52 (20060101)|
|Field of Search:||424/422,423,451,452,457,464,465,468,489 514/282,289|
|2770569||November 1956||Fromherz et al.|
|3133132||May 1964||Loeb et al.|
|3332950||July 1967||Blumberg et al.|
|3493657||February 1970||Lewenstein et al.|
|3541005||November 1970||Strathmann et al.|
|3541006||November 1970||Bixler et al.|
|3676557||July 1972||Lachman et al.|
|3773955||November 1973||Pachter et al.|
|3879555||April 1975||Pachter et al.|
|3966940||June 1976||Pachter et al.|
|4160020||July 1979||Ayer et al.|
|4200098||April 1980||Ayer et al.|
|4285987||August 1981||Ayer et al.|
|4401672||August 1983||Portoghese et al.|
|4443428||April 1984||Oshlack et al.|
|4457933||July 1984||Gordon et al.|
|4464378||August 1984||Hussain et al.|
|4573995||March 1986||Chen et al.|
|4582835||April 1986||Lewis et al.|
|4661492||April 1987||Lewis et al.|
|4730048||March 1988||Portoghese et al.|
|4760069||July 1988||Rzeszotarski et al.|
|4785000||November 1988||Kreek et al.|
|4806341||February 1989||Chien et al.|
|4806558||February 1989||Wuest et al.|
|4828836||May 1989||Elger et al.|
|4834965||May 1989||Martani et al.|
|4834984||May 1989||Goldie et al.|
|4834985||May 1989||Elger et al.|
|4844907||July 1989||Elger et al.|
|4844909||July 1989||Goldie et al.|
|4844910||July 1989||Leslie et al.|
|4861598||August 1989||Oshlak et al.|
|4867985||September 1989||Heafield et al.|
|4873076||October 1989||Fishman et al.|
|4889860||December 1989||Rzeszotarski et al.|
|4940587||July 1990||Jenkins et al.|
|4987136||January 1991||Kreek et al.|
|4990341||February 1991||Goldie et al.|
|5071646||December 1991||Malkowska et al.|
|5075341||December 1991||Mendelson et al.|
|5086058||February 1992||Sinclair et al.|
|5091189||February 1992||Heafield et al.|
|5130311||July 1992||Guillaumet et al.|
|5149538||September 1992||Granger et al.|
|5225440||July 1993||London et al.|
|5226331||July 1993||Thompson et al.|
|5236714||August 1993||Lee et al.|
|5256669||October 1993||Askanazi et al.|
|5266331||November 1993||Oshlak et al.|
|5273760||December 1993||Oshlak et al.|
|5286493||February 1994||Oshlak et al.|
|5316759||May 1994||Rose et al.|
|5317022||May 1994||Borsodi et al.|
|5321012||June 1994||Mayer et al.|
|5324351||June 1994||Oshlak et al.|
|5336691||August 1994||Raffa et al.|
|5352680||October 1994||Portoghese et al.|
|5352683||October 1994||Mayer et al.|
|5356467||October 1994||Oshlak et al.|
|5356900||October 1994||Bihari et al.|
|5409944||April 1995||Black et al.|
|5411745||May 1995||Oshlack et al.|
|5411965||May 1995||Reid et al.|
|5426112||June 1995||Zagon et al.|
|5436265||July 1995||Black et al.|
|5457208||October 1995||Portoghese et al.|
|5460826||October 1995||Merrill et al.|
|5472712||December 1995||Oshlack et al.|
|5472943||December 1995||Crain et al.|
|5474995||December 1995||Ducharme et al.|
|5478577||December 1995||Sackler et al.|
|5486362||January 1996||Kitchell et al.|
|5500227||March 1996||Oshlack et al.|
|5502058||March 1996||Mayer et al.|
|5508042||April 1996||Oshlack et al.|
|5510368||April 1996||Lau et al.|
|5512578||April 1996||Crain et al.|
|5514680||May 1996||Weber et al.|
|5521213||May 1996||Prasit et al.|
|5534492||July 1996||Aston et al.|
|5536752||July 1996||Ducharme et al.|
|5549912||August 1996||Oshlack et al.|
|5550142||August 1996||Ducharme et al.|
|5552406||September 1996||Mendelson et al.|
|5552422||September 1996||Gauthier et al.|
|5556838||September 1996||Mayer et al.|
|5574052||November 1996||Rose et al.|
|5578725||November 1996||Portoghese et al.|
|5580876||December 1996||Crain et al.|
|5585348||December 1996||Crain et al.|
|5591452||January 1997||Miller et al.|
|5593994||January 1997||Batt et al.|
|5601845||February 1997||Buxton et al.|
|5604253||February 1997||Lau et al.|
|5604260||February 1997||Guay et al.|
|5616601||April 1997||Khanna et al.|
|5622722||April 1997||Knott et al.|
|5624932||April 1997||Qin et al.|
|5633259||May 1997||Qin et al.|
|5639476||June 1997||Oshlack et al.|
|5639780||June 1997||Lau et al.|
|5656295||August 1997||Oshalck et al.|
|5670172||September 1997||Buxton et al.|
|5672360||September 1997||Sackler et al.|
|5681585||October 1997||Oshlack et al.|
|5763452||June 1998||Miller et al.|
|5767125||June 1998||Crain et al.|
|5780051||July 1998||Eswara et al.|
|5843480||December 1998||Miller et al.|
|5849240||December 1998||Miller et al.|
|5858017||January 1999||Demopulos et al.|
|5860950||January 1999||Demopulos et al.|
|5866164||February 1999||Kuczynski et al.|
|5869097||February 1999||Wong et al.|
|5879705||March 1999||Heafield et al.|
|5891471||April 1999||Miller et al.|
|5908848||June 1999||Miller et al.|
|5942241||August 1999||Chasin et al.|
|5958452||September 1999||Oshlack et al.|
|5958459||September 1999||Chasin et al.|
|5965161||October 1999||Oshlack et al.|
|5965163||October 1999||Miller et al.|
|5968547||October 1999||Reder et al.|
|5968551||October 1999||Oshlack et al.|
|5998434||December 1999||Mitch et al.|
|6004970||December 1999||O'Malley et al.|
|6024982||February 2000||Oshlack et al.|
|6068855||May 2000||Leslie et al.|
|6077532||June 2000||Malkowska et al.|
|6077533||June 2000||Oshlack et al.|
|6096756||August 2000||Crain et al.|
|6103261||August 2000||Chasin et al.|
|6143322||November 2000||Sackler et al.|
|6143328||November 2000||Heafield et al.|
|6162467||December 2000||Miller et al.|
|6194382||February 2001||Crain et al.|
|6210714||April 2001||Oshlack et al.|
|6228863||May 2001||Palermo et al.|
|6254887||July 2001||Miller et al.|
|6258379||July 2001||Weinstein et al.|
|6261599||July 2001||Oshlack et al.|
|6274591||August 2001||Foss et al.|
|6277384||August 2001||Kaiko et al.|
|6294195||September 2001||Oshlack et al.|
|6306438||October 2001||Oshlack et al.|
|6326027||December 2001||Miller et al.|
|6335033||January 2002||Oshlack et al.|
|6362194||March 2002||Crain et al.|
|6375957||April 2002||Kaiko et al.|
|6387404||May 2002||Oshlack et al.|
|6395705||May 2002||Crain et al.|
|6399096||June 2002||Miller et al.|
|6475494||November 2002||Kaiko et al.|
|6552031||April 2003||Burch et al.|
|6627635||September 2003||Palermo et al.|
|6696066||February 2004||Kaiko et al.|
|6696088||February 2004||Oshlack et al.|
|6716449||April 2004||Oshlack et al.|
|6765010||July 2004||Crain et al.|
|7144587||December 2006||Oshlack et al.|
|7172767||February 2007||Kaiko et al.|
|2001/0006967||July 2001||Crain et al.|
|2001/0008639||July 2001||Oshlack et al.|
|2001/0018413||August 2001||Crain et al.|
|2002/0058673||May 2002||Kaiko et al.|
|2003/0004177||January 2003||Kao et al.|
|2003/0068371||April 2003||Oshlack et al.|
|2003/0073714||April 2003||Breder et al.|
|2003/0157168||August 2003||Breder et al.|
|2003/0191147||October 2003||Sherman et al.|
|2004/0092542||May 2004||Oshlack et al.|
|2004/0186121||September 2004||Oshlack et al.|
|2004/0192715||September 2004||Chasin et al.|
|2004/0228924||November 2004||Oshlack et al.|
|2005/0095291||May 2005||Oshlack et al.|
|2005/0181046||August 2005||Oshlack et al.|
|2005/0245483||November 2005||Brogmann et al.|
|2005/0245556||November 2005||Brogmann et al.|
|2005/0245557||November 2005||Schoenhard et al.|
|2006/0039970||February 2006||Oshlack et al.|
|2006/0182801||August 2006||Breder et al.|
|2006/0194826||August 2006||Oshlack et al.|
|2007/0122348||May 2007||Kaiko et al.|
|2008/0020028||January 2008||Shevchuk et al.|
|WO 95/28963||Nov., 1995||WO|
|WO 99/32119||Jul., 1999||WO|
|WO 99/32120||Jul., 1999||WO|
|WO 9932120||Jul., 1999||WO|
|WO 00/54774||Sep., 2000||WO|
Philip D. Kanof et al., "Levels of Opioid Physical Dependence in Heroin Addicts," Drug and Alcohol Dependence, 27 (1991) 253-262. cited by other .
J.E. Peachey et al., "Assessment of Opioid Dependence with Naloxone," British Journal of Addiction (1988) 83(2), 193-201. cited by other .
John G. Nutt et al., "Methadone-naloxone Mixtures for Use in Methadone Maintenance Prograpms," Clinical Pharmacology and Therapeutics, vol. 15, No. 2, pp. 156-166, received for publication Jun. 11, 1973. cited by other .
Richard I. H. Wang et al., "Rating the Presence and Severity of Opiate Dependence," Clinical Pharmacology and Therapeutics, vol. 16, No. 4, pp. 653-657; received for publication Jan. 21, 1974. cited by other .
Richard B. Resnick et al., "Naloxone Precipitated Withdrawal: A Method for Rapid Induction Onto Naltrexone," Clinical Pharmacology and Therapeutics, vol. 21, No. 4, pp. 409-413; received for publication Nov. 16, 1976. cited by other .
Barbara A. Judson et al., "The Naloxone Test Opiate Dependence," Clin. Pharmacol. Ther., vol. 27, No. 4, pp. 492-501, received for publication Sep. 15, 1979. cited by other .
Philip D. Kanof et al., "Clinical Characteristics of Naloxone-Precipitated Withdrawal in Human Opioid-Dependent Subjects," The Journal of Pharmacology and Experimental Therapeutics, vol. 260, No. 1, pp. 355-363, 1992. cited by other .
Richard L. Wiesen et al., "The Safety and Value of Naloxone as a Therapeutic Aid," Drug and Alcohol Dependence, 2 (1977) pp. 123-130. cited by other .
"Field of Chemical Therapy," 1998, vol. 14, No. 6, pp. 86-88. cited by other .
Foss, J.F., et al.Abstract, "Prevention of Apomorphine- or Cisplatin- induced emesis in the dog by combination of Methylnaltrexone and Morphine",Cancer Chemother Pharmacol (1998); 42(4):287-91. cited by other .
Yuan et al., "Efficacy of Orally Administered Methylnaltrexone in Decreasing Subjective Effects After Intravenous Morphine",Drug and Alcohol Dependence (1998); 52:161-165. cited by other .
Gan et al., "Opioid-Sparing Effects of a Low-Dose Infusion of Naloxone in Patient-Administered Morphine Sulfate," Anesthesiology (1997), 87(5):1075-1080. cited by other .
Shen et al., "Ultra-Low Doses of Naltrexone or Etorphine Increase Morphine's Antinocieceptive Potencey and Attenuate Tolerance/Dependence in Mice," Brain Research (1997), 757:176-190. cited by other .
Yuan et al., "The Safety and Efficacy of Oral Methylnaltrexone in Preventing Morphine-induced Delay in Oral-Cecal Transit Time", Clinical Trials and Therapeutics (1997), 61:467-475. cited by other .
Mendelson J., et al, "Buprenorphine and Naloxone Interactions in Opiate Dependent Volunteers" Clin. Phar. Ther. (1996), 60:105-114. cited by other .
Walsh et al., "Effects of Naltrexone on Response to Intravenous Cocain, Hydromorphone and their Combination in Humans," (1996). cited by other .
Chih-Cheng Chien, et al., "Sigma Antagonists Potentiate Opioid Analgesia in Rats", Neuroscience Letters 190 (1995), 137-139. cited by other .
Crain et al., "Ultra-Low Concentrations of Naloxone Selectively Antagonize Excitory Effects of Morphine on Sensory Neurons, Thereby Increasing Its Antinociceptive Potency and Attenuating Tolerance/Dependence During Chronic Cotreatment," Proc. Natl. Acad. Sci. USA (1995) 92:10540-10544. cited by other .
Hanson, Analgesic, Antipyretic and Anti-Inflammatory Drugs in Remington's Science and Practice of Pharmacy (1995), 2:1207. cited by other .
Talwin NX, Physician's Desk Reference 48.sup.th Ed. (1994) Montvale, NJ 2120-2121. cited by other .
Foss et al., "Dose related Antagonism of the Emetic Effect of Morphine by Methylnaltrexone in Dogs",J. Clin Pharmacol (1993), 33:747-751. cited by other .
Holmes et al., "Inhibiting Spinal Dynorphin A Component Enhances Intrathecal Morphine Antinocicption in Mice", Anesth. Analg. (1993), 77:1166-73. cited by other .
Miakowski et al., "Inhibition of Spinal Opioid Analgesia by Supraspinal Administration of Selective Opioid Antagonists", Brain Research (1992), 30:263-274. cited by other .
Weinhold et al., "Buprenorphine Alone and in Combination with Naltrexone in Non-Dependent Humans," Drug and Alcohol Dependence (1992), 30:263-274. cited by other .
Cappel et al., "Enhancement of Naloxone Induced Analgesia by Pretreatment with Morphine" Pharma. Bioch. & Behav. (1989), 34:425-427. cited by other .
Vaccarino et al.,"Analgesia Produced by Normal Doses of Opioid Antagonists Alone and in Combination with Morphine", Pain (1989), 36:103-109. cited by other .
Gonzalez et al., "Naltrexone: A Review of its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Efficacy in the Management of Opioid Dependence," Drugs (1988), 35:192-213. cited by other .
Sunshine, et al., "Analgesic Efficacy of Pentazocine Versus a Pentazocine-Naloxone Combination Following Oral Administration," Clin. J. Pain (1988), 4:35-40. cited by other .
Wang et al., "Crossover and Parallel Study of Oral Analgesics," J. Clin. Pharmacol (1981), 21:162-168. cited by other .
Alavrez-Fuentes, et al. "Effectiveness of Repeated Administration of a New Ora Naltrexone Controlled-Release System in Morphine Analgesia"; J. Pharm Pharmcaol (2001), 53:1201-1205. cited by other .
Alvarez-Fuentes, et al., :Preclinical Study of an Oral Controlled Release Naltrexone Complex in Mice; J. Pharm Pharmacol (2000), 52:659-663. cited by other .
Archer, Sydney; "Historical Perspective on the Chemistry and Development of Naltrexone"; Naltrexone Research Monograph28 (1980) p. 3-9. cited by other .
Baum et al., "The Impact of the Addition of Naloxone on thr Use and Abuse of Pentazocine"; Public Health Reports (1987) vol. 102, No. 4 p. 426-429. cited by other .
Rapaka et al., "Discovery of Novel Opioid Medications"; NIDA Research Monograph 147 (1995) p. 55-83. cited by other .
Bloom et al., "Clinical Studies with Naloxone/Methadone in a Ratio of 1:20"; 5.sup.th National Conference on Methadone Treatment (1973) vol. 2, p. 1342-1349. cited by other .
Briscoe et al., "Methoclocinnamox: Time Course of Changes in Alfetnanil-Reinforced Rhesus Monkeys"; Psychopharmacology (2000) 148:393-399. cited by other .
Abstract of Bromm, et al., "A Sensitive Method to Evaluate Effects of Analgesics in Man"; Meth and Find Exptl Clin Pharmacol 5 (8) (1983) p. 545-551. cited by other .
Bullingham et al., "Clinical Pharamcokinetics of Narcotic Agonist-Antagonist Drugs"; Clinical Pharm (1983) 8: 332-343. cited by other .
Calimlim, et al. "Effect of Naloxone on the Analgesic Activity of Methadone in a 1:10 Oral Combination"; Clin Pharmacol and There (1974) vol. 15; No. 6 pp. 556-564. cited by other .
Chemy, Nathan I., "Opioid Analgesics"; Drugs (May 1996):51 (5) pp. 713-737. cited by other .
.Chiang, et al. "Clinical Evaluation of a Naltrexone Sustained-Release Preparation"; Drug and Alcohol Dependence (1985) 16, pp. 1-8. cited by other .
Chiang et al., "Kinetics of a Naltrexone Sustained-Release Preparation"; Clin Pharmacol Thera (1984) vol. 36 No. 5, pp. 704-708. cited by other .
Comer et al., "Depot Naltrexone: Long-lasting Antagonism of the Effects of Heroin un Humans"; Psychopharmacology (2002) 159, pp. 351-360. cited by other .
Crabtree et al., "Review of Naltrexone, a long-acting Opiate Antagonist"; Clinical Pharmacy, vol. 3 (1984) pp. 273-280. cited by other .
Crain et al., "Antagonists of Excitatory Opioid Receptor Functions Enhance Morphine's Analgesic Potency and Attenuate Opioid Tolerance/dependence liability"; Dept. of Neuroscience, Albert Einstein College of Medicine Pain 82 (1999)pp. 1-11. cited by other .
Crain et al., "Antagonists of Excitatory Opioid Receptor Functions Enhance Morphine's Analgesic Potency and Attenuate Opioid Tolerance/dependence liability"; Dept. of Neuroscience, Albert Einstein College of Medicine Pain 84 (2000) pp. 121-131. cited by other .
.Fishman et al., "Disposition of Naloxone-7,8-.sup.3H in Normal & Narcotic Dependent Men"; J. Pharm. and Exper. Thera (1973)vol. 10 No. 2;pp. 575-580. cited by other .
Fraser, Albert D., et al., "Clinical Toxicology of Drugs Used in the Treatment of Opiate Dependency"; Clinical Toxicology I (1990) vol. 10, No. 2; pp. 375-386. cited by other .
Freye et al., effects of Tramadol and Tilidine/Naloxone on Oral-Caecal Transit & Pupillary light Reflex; Arzneim-Forsch/Drug Res. 50(I)(2000)pp. 24-30. cited by other .
Fudala, et al., "Effects of Buprenorphine asnd Naloxone in Morphine-Stabilized Opioid Addicts"; Drug and Alcohol Dependence 50 (1998) pp. 1-8. cited by other .
Fudala et al., "Human Pharmacology and Abuse Potential of Nalmefene"; Clin Pharm and Thera (1991) vol. 49, 3, pp. 300-306. cited by other .
Gal et al., "Prolonged Blockade of Opioid Effect with Oral Nalmefene"; Clin Pharm and Thera (1986) pp. 537-542. cited by other .
Gerra et al., "Clonidine and Opiate Receptor Antagonists in the Treatment of Heroin Addiction"; J. Substance Abuse Treatment (1995) vol. 12, 1, pp. 35-41. cited by other .
Ghodse, et al., "Opioid analgesics and Narcotic Antagonists"; Side Effects of Drugs (2000) Annual 23, chpt 8 pp. 96-113. cited by other .
Glatt, William, M.D. FACP, "A New Method for Detoxifying Opoiod-Dependent Patients"; J. Substance Abuse Treatment (1999) vol. 17, No. 3,pp. 193-197. cited by other .
Gold, et al. "Rapid Opioid Detoxification During General Anesthesia"; Anesthesiology (1999) vol. 91, No. 6, pp. 1639-1647. cited by other .
Greenwald, et al., "Comparative Clinical Pharmacology of Short-Acting .mu..upsilon. Opioids in Drug Abusers"; J. Pharm and Exper Thera (1996) vol. 277, No. 3, pp. 1228-1236. cited by other .
Gupta, et al., :Morphine Combined with Doxapram or Naloxone; Anesthesia (1974) vol. 29, pp. 33-39. cited by other .
Richter et al., "Clinical Investigation on the Development of Dependence during Oral Therapy with Tramadol"; Arzniem-Forsch/Drug Res. 35 (No. II)(1985)pp. 1742-1744. cited by other .
Rosen et al., "The effect of Lamotrigine on Naloxone-precipitated Opiate withdrawal"; Drug and Alcohol Dependence (1998) vol. 52, pp. 173-176. cited by other .
Rosen et al., "A Pilot Study of Dextromethorphan in Naloxone-Precipitated Opiate Withdrawal"; European J. of Pharm. (1996) vol. 307, pp. 251-257. cited by other .
Schuh et al., "Buprenorphine, Morphine and Naloxone Effects during Ascending Morphine Maintenance in Humans"; J. Pharm and Exper Thera (1996) vol. 278, 2, pp. 836-846. cited by other .
Schuh et al., "Onset, Magnitude and Duration of Opioid Blockade Produced by Buprenorphine and Naltrexone in Humans"; Psychopharmacology (1999) vol. 145, pp. 162-174. cited by other .
Stevens et al., Nonspecific Excitatory Effects of Morphine: Reverse-Order Precipitated Withdrawal and Dose-Dose Interactions': Psychopharmacology (1981) vol. 75, pp. 210-211. cited by other .
Stine et al., "Reduction of Opiate Withdrawal-like Symptoms by Cocaine Abuse during Methadone and Buprenorphine Maintenance"; Am. J. Drug and Alcohol Abuse (1994) vol. 20, 4, pp. 445-458. cited by other .
Stine et al., "Use of Drug Combinations in Treatment of Opiopd Withdrawal"; J. Clinical Psych. (1992) vol. 12, No. 3, pp. 203-209. cited by other .
Stoller et al., "Effects of buprenorphine/naloxone in opioid-dependent humans" Psychopharmacology (2001) vol. 154, pp. 230-242. cited by other .
Strain et al., "Acute Effects of Buprenorphine, hydromorphone and naloxone in methadone-maintained volunteers"; J. Pharm and Exper Thera (1992) vol. 261, No. 3, pp. 985-993. cited by other .
Strain et al., "Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers"; Psychopharmacology (2000) vol. 148, pp. 374-383. cited by other .
Strain et al., "Precipitated Withdrawal by Pentazocine in Methadone-Maintained Volunteers"; J. Pharm and Exper Thera (1993) vol. 267, No. 2, pp. 624-634. cited by other .
Tai, et al., "Naltrexone: An Antagonist Therapy for Heroin Addiction"; NIDA (1997) 5 pages. cited by other .
Umbricht et al., "Naltrexone shortened opioid detoxification with buprenorphine"; Drug and Alcohol Dependence (1999) vol. 56 pp. 181-190. cited by other .
Vaccarino et al., "Enogenous Opiates: 1999"; Peptides 21 (2000) pp. 1975-2034. cited by other .
Wang et al., "Inverse Agonists and neutral antagonists at .mu. opioid receptor (MOR): possible role of basal receptor signaling in narcotic dependence"; J. Neurochemistry (2001) vol. 77, pp. 1590-1600. cited by other .
Weinberg et al., "Sublingual absorption of selected opioid analgesics"; Clin Pharm Thera (1988) vol. 44, No. 3, pp. 335-342. cited by other .
Wells, et al., "In vivo Pharmacological Characterization of SoRI 9409, a Nonpeptidic Opioid .mu.-Agonist/.delta.-Antagonist that Produces Limited Antinociceptive Tolerance and Attenuates Morphione Physical Dependence"; J. Pharm and Exper Thera (2001) vol. 297, No. 2, pp. 597-605. cited by other .
Wodak, Alex, "Drug Treatment for Opioid Dependence"; Australian Prescriber (2001) vol. 24, No. 1, pp. 4-6. cited by other .
Wright et al., "Acute physical dependence in Humans; repeated naloxone-precipitated withdrawal after a single-dose of methadone"; Drug and Alcohol Dependence (1991) vol. 27, pp. 139-148. cited by other .
Zhu et al., "Naltrexone-precipitated morphine withdrawal in infant rat is attenuated by acute administration if NOS inhibitors but not NMDA receptor antagonists"; Psychopharmacology (2000) vol. 150, pp. 325-336. cited by other .
Han et al., "Muccoadhesive buccal disks for novel nalbuphine prodrug controlled delivery; effect of formulation variable on drug release and mucoadhesive performance"; International J. Pharm (1999) vol. 177, pp. 201-209. cited by other .
Handal et al., "Naloxone"; Annals of Emergency Medicine (1983) vol. 12:7, pp. 438-445. cited by other .
Harris et al., "Buprenorphine and Naloxone co-administration in opiate dependent patients stabilized on sublingual buprenorphine"; Drug and Alcohol Dependence (2000) vol. 61, pp. 85-94. cited by other .
Hawkes et al., "Effect of enteric-release formulation of naloxone on intestinal transit in volunteers taking codeine"; Aliment Pharm Ther (2001) vol. 15, pp. 625-630. cited by other .
Hogger et al., "Comparison of tilidine/naloxone, tramadol and bromfenac in experimental pain: a double-blind randomized crossover study in healthy human volunteers"; International J. Clin Pharm and Thera (1999) vol. 37, No. 8,pp. 377-385. cited by other .
Budd, Keith, "Clinical Use of Opioid Antagonists"; Bailliere's Clinical Anesthesiology (1987) vol. 1, No. 4, pp. 993-1011. cited by other .
Howes et al., "The Pharmacology of TR5109, a new Narcotic Agonist/Antagonist Analgesic"; NIDA Research (1979) pp. 99-105. cited by other .
Leeling et al., "Disposition and metaboliam of codorphone in the rat, dog, and man"; Drug Metabolism and Disposition (1982) vol. 10, No. 6, pp. 649-653. cited by other .
Amass et al., "Efficacy of daily and alternate-day dosing regimens with the combibation buprenorphine-naloxone tablet"; Drug and Alcohol Dependence (2000) vol. 58, pp. 143-152. cited by other .
Hassain et al., "Buccal and oral bioavailability of naloxone and naltrexone in rats";(1987) vol. 36, pp. 127-130. cited by other .
Jasinski et al., "The human pharmacology and abuse potential of N-allylnoroxymorphone naloxone"; J. Pharm and Exper Thera (1967) vol. 157, No. 2, pp. 420-426. cited by other .
Jones et al., Nalmefene:blockade of intravenous morphine challenge effects in opioid abusinh humans; Drug and Alcohol Dependence (2000) vol. 60, pp. 29-37. cited by other .
Kanof et al., "Clinical Charateristics of Naloxone-Precipitated Withdrawal in Human Opioid-Dependent Subjects"; J Pharma and Exper Thera (19920 vol. 260, No. 1, pp. 355-363. cited by other .
King et al, Naltrexone Biotransformation and Incidence of Subjective Side Effects: A Preliminary Study; Alcoholism: Clin and Exper Res (1997) vol. 21, No. 5, pp. 906-909. cited by other .
Kogan et al., "Estimation of the Systemic Availability and Other Pharmacokinetic Parameters of Naltrexone in Man after Acute and Chronic Oral Administration"; Res. Comm. In Chem. Path. And Pharm (1977) vol. 18, No. 1, pp. 29-34. cited by other .
Kosten, Thomas R., M.D.,"Buprenorphine for Benzodiazepine-Abusing Heroin Addicts"; Amer J of Phsychiatry (1994) vol. 1, p. 151. cited by other .
Kosten et al., "Opioid antagonist challenges in buprenorphine maintained patients"; Drug and Alcohol Dependence (1990) vol. 25, OO. 73-78. cited by other .
Kurland et al., "Naloxone and the Narcotic Abuser: A Controlled Study of Partial Blockade"; Inter. J. of the Addictions (1974) vol. 9, No. 5, pp. 663-672. cited by other .
Lee et al., "Nalbuphine Coadministered with Morphine Prevents Tolerance and Dependence"; Anesth Analg (1997) vol. 84, pp. 810-815. cited by other .
Lehman, et al.,"Influence of Naloxone on the Postoperative Analgesic and Respiratory effects of Buprenorphine"; Eur. J. Clin Pharm (1988) vol. 34, pp. 343-352. cited by other .
Levine et al., "Potentiation of Pentazocine Analgesia by Low-dose Naloxone"; J Clin Invest (1988) vol. 82, pp. 1574-1577. cited by other .
Loimer et al., "Combined Naloxone/Methadone Preparations for Opiate Substitution Therapy"; J. of Substance Abuse Treatment (1991) vol. 8, pp. 157-160. cited by other .
Martin et al. "Bioavailability Investigation of a New Tilidine/Naloxone Liquid Formulation Compared to a Reference Formulation"; Arzneim-Forsch./Drug Res. (1999) vol. 49, pp. 599-607. cited by other .
Martin et al., "Demonstration of Tolerance to and Physical Dependence on N-allynormorphine (Nalorphine)";J. Of Pharm and Exper Thera (1965) vol. 150, No. 3. pp. 437-442. cited by other .
Mendelson et al., "Buprenorphine and naloxone combinations: the effects of three dose ratios in morphine stabilized, opiate-dependent volunteers"; Psychopharmacology (1999) vol. 141, pp. 37-46. cited by other .
Mendelson et al., "Buprenophine and naloxone Interactions in Methadone Maintenance Patients"; Society of Biological Psychiatry (1997) vol. 41, pp. 1095-1101. cited by other .
Pitts et al., "Antinociceptive and Response Rate-Altering Effects of Kappa Opioid Agonists, Spiradoline, Enadoline and U69,593, Alone and in Combination with Opioid Antagonists in Squirrel Monkeys"; J of Pharm and Exper Them (1994) vol. 271, No. 3, pp. 1501-1508. cited by other .
Preston et al., "Buprenorphine and Naloxone alone and in combination in Opioid-dependant Humans"; Psychopharmacology (1988), vol. 94, pp. 484-490. cited by other .
Preston et al., "Differential Naltrexone Antagonism of Hydromorphone and Pentazocine Effects in Human Volunteers"; J of Pharm and Ezper Thera (1993) vol. 264, No. 2 pp. 813-823. cited by other .
Preston et al., "Effects of Sublingually given naloxone in Opioid -dependant human volunteers"; Drug and Alcohol Dependence (1990) vol. 25, pp. 27-34. cited by other .
Wikler et al., "N-Allylnormorphine: Effects of single dose and Precipitation of Acute "Abstinence Syndromes" during addiction to morphine, methadone or heroin in man (post addicts)"; N-Allylnormorphine During Narcoctic Addiction (1953) pp. 8-20. cited by other .
Zaks et al., "Naloxone Treatment of Opiate Dependence"; JAMA (1971) vol. 215, No. 13, pp. 2108-2110. cited by other .
Barton, et al., "Intranasal Administration of Naloxone by Paramdeics";Prehospital Emergency Care (2002) vol. 6, No. 1, pp. 54-58. cited by other .
Blachly, Paul, H., M.D., "Naloxone in Opiate Addiction"; Current Psychiatric Therapies (1976) pp. 209-213. cited by other .
Bashaw et al., "Relative bioavailability of controlled-release oral morphine sulfate during naltrexone blockade"; Inter J of Clin Pharm and Thea (1995) vol. 33, No. 9, 524-529. cited by other .
Jasinski, D.R., "Assessment of the Abuse Poteniality of Morphinelike Drugs (Methods Used in Man)"; Drug Addiction (1977) pp. 197-258. cited by other .
Johnson et al., "Buprenorphine and Naloxone for Heroin Dependence"; Substance Use Disorders (2000) pp. 519-526. cited by other .
Strain et al., "Opioid antagonist effects of dezocine in opioid-dependent humans"; Clin Pharm and Thera (1996) vol. 60, No. 2, pp. 206-217. cited by other .
Preston et al., "Abuse liability and studies of opioid agonist-antagonists in humans"; Drug and Alcohol Dependence (1991) vol. 28, pp. 49-82. cited by other .
Brennscheidt et al., "Pharmacokinetics of Nortilidine and Naloxone after Administration of Tilidine/Naloxone Solution or Tilidine/Naloxone Sustained Release Tablets"; Arzeim-Forsch/Drug Res. (2000) vol. 50, pp. 1015-1022. cited by other .
Benfey, "Function of Myocardial .alpha.-Adrenoceptors" ; Life Sciences (1982) vol. 31, pp. 101-112. cited by other .
Levine et al., "Potentiation of Pentazocine Analgesia by Low-dose Naloxone"; J of Clin Invest. (1988) vol. 82, pp. 1547-1577. cited by other .
Yoburn et al., Opioid Antagonist-induced Receptor Upregulation: Effects of Concurrent Agonist Administration; Brain Research Bulletin (1994), vol. 33, pp. 237-240. cited by other .
Bunzow et al., "Molecular Closing and Tissue Distribution of a Putative Member of the Rat Opioid Receptor Gene Family that is not a .mu., .delta., or .kappa. opioid receptor type"; FEBS letters (1994) pp. 284-288. cited by other .
Mollereau et al., "ORL 1, a novelmember of the opioid receptor family: Cloning, functional expression and localization"; FEBS letters 341 (1994), pp. 33-38. cited by other .
Wang, et al.,"cDNA cloning a=of an orphan opiate receptor gene family member and its splice variant"; FEBS letters 348 (1994) pp. 75-79. cited by other .
Suzuki et al., "Morphine conditioned place preference after chronic treatment with naloxone in the rat"; Research Communications in Substance Abuse (1991) vol. 12., No. 3., pp. 119-131. cited by other .
Press Release "International Patent Application to Be Published on Abuse-Resistant Pain Reliever Being Developed by Perdue Pharma"; Aug. 8, 2001. cited by other .
Paronis et al., "Increased Analgesic Potency of Mu Agonists after Continuous Naloxone Infusion in Rats"; J fo Pharm Exper Thera (1991), 259 (2), pp. 582-589. cited by other .
Yoburn et al., "Supersensitivity to Opioid Analgesics Following Chronic Opioid Antagonist Treatment: Relationship to Receptor Sensitivity"; Pharmacology Bio Beh (1995) vol. 51 No. 2, pp. 535-539. cited by other .
Crain et al., "Acute thermal hyperalgesia elicited by low-dose morphine in normal mice is blocked by ultra-low-dose naltrexone, unmasking potent opioid analgesia"; Brain Research (2001) vol. 888, pp. 75-82. cited by other .
Zhang et al., "Down-Regulation of .mu.-Opioid Receptors in Rat and Monkey Dorsal Root Ganglion Neurons and Spinal Cord After Peripheral Axotomy"; Neuroscience (1998) vol. 82., pp. 223-240. cited by other .
Abdulla et al., "Axotomy reduces the effect of analgesic opioids yet increases the effect of nociceptin on dorsal root ganglion neurons"; J of Neuro Sci (1998) vol. 18, pp. 9685-9694. cited by other .
Di Giannuario et al., Orphanin FQ reduces morphine-induced dopamine release in the nucleus accumbens: a microdialysis study in rats; Neurosci. Lett (1999) vol. 272 pp. 183-186. cited by other .
Ciccocioppo et al., "Effect of Nociceptin/orphanin FQ on the Rewarding Properties of Morphine"; Eur. J Pharmacol (2000) vol. 404, pp. 153-159. cited by other .
Physician's Desk Reference (2001) see Revia, pp. 1146-1149 and Oxycontin, pp. 2697-2701. cited by other .
Translation of German patent application DE 43 25 465 published Feb. 2, 1995. cited by other .
Translation of claims of DE 297 197 04, Nov. 6, 1997. cited by other .
Caruso et al., "Methadone and Naloxone in Combination (Naldone.RTM.) for the Treatment if Heroin Addicts"; Bristol Laboratories, pp. 1336-1341F, (1973). cited by other .
Fink et al., "Naloxone in Heroin Dependence"; Clin Pharm and Thera. vol. 9, No. 5;pp. 568-577, (1968). cited by other .
Way et al., "Responsivity to Naloxone during Morphine Dependence"; Annals New York Academy of Sciences, pp. 252-261, (1976). cited by other .
Crain et al., Ultra-low concentrations of naloxone selectively antagonize excitatory effects of morphine on sensory neurons, thereby increasing its antinociceptive potency and attenuating tolerance/dependence, (1995). cited by other .
Nutt et al., "Methadone-naloxone mixture for use in methadone maintenance programs"; Clin Pharm and Ther. vol. 15, No. 2., pp. 156-166, (1973). cited by other .
Parwatikar et al., "Methadone-naloxone in combination for the Treatment of Heroin Addicts"; Clin. Pharm and Thera, vol. 14, No. 6, pp. 941-948 (1973). cited by other .
Parwartikar et al., "Naloxone-Methadone Combination for the Treatment of Opiate Dependence"; Missouri Institute of Psychiatry, pp. 1350-1354, (1973). cited by other .
Bigelow et al., "Abuse Liability and Assessment of Buprenorphine-Naloxone Combinations"; Dept of Psychiatry and Behavioral Sciences, The Johns Hopkins University School of Medicine, pp. 145-149, (1987). cited by other.